Table 1.
Baseline demographic, clinical, and laboratory disease parameters of SSc patients.
| Characteristics | N | SSc, N = 18 1 |
|---|---|---|
| Age (years) | 18 | 50 (45, 56) |
| Gender | 18 | |
| female | 18 (100%) | |
| Disease duration (years) | 18 | 4.0 (2.2, 9.2) |
| Disease duration (early ≤3 years; late 3 years) | 18 | |
| early | 7 (39%) | |
| late | 11 (61%) | |
| SSc subtype | 18 | |
| diffuse cutaneous | 9 (50%) | |
| limited cutaneous | 8 (44%) | |
| sine scleroderma | 1 (6%) | |
| Esophagitis | 15 | 6 (40%) |
| unknown | 3 | |
| ILD | 18 | 11 (61%) |
| Arrhythmias requiring therapy | 18 | 1 (5.6%) |
| Arthritis | 18 | 1 (5.6%) |
| Digital ulcers | 18 | |
| current | 5 (28%) | |
| never | 8 (44%) | |
| previous | 5 (28%) | |
| Calcinosis | 18 | 4 (22%) |
| Telangiectasia | 18 | 8 (44%) |
| mRSS | 16 | 5.5 (4.0, 8.8) |
| unknown | 2 | |
| ANA | 18 | |
| negative | 1 (6%) | |
| positive | 17 (94%) | |
| Anti-Scl-70 | 18 | |
| negative | 7 (39%) | |
| positive | 11 (61%) | |
| Anti-centromere | 6 | |
| negative | 1 (17%) | |
| positive | 5 (83%) | |
| unknown | 12 | |
| Rheumatoid factor | 17 | |
| negative | 12 (70%) | |
| positive | 5 (30%) | |
| unknown | 1 | |
| CRP (mg/dL) | 18 | 0.19 (0.14, 0.33) |
| ESR (mm/h) | 18 | 9 (6,15) |
| Uric acid (mg/dL) | 17 | 4 (3.28–5.1) |
| unknown | 1 | |
| FVC (% predicted) | 8 | 93 (88–96.5) |
| unknown | 10 | |
| DLCO (% predicted) | 6 | 66 (66–74) |
| unknown | 12 | |
| LVEF (%) | 13 | 62 (59–65) |
| unknown | 5 |
1 median (IQR); n (%). SSc = systemic sclerosis; ILD = interstitial lung disease; mRSS = modified Rodnan skin score; ANA = antinuclear antibodies; CRP = C reactive protein; ESR = erythrocyte sedimentation rate; FVC = forced vital capacity; DLCO = diffusing capacity of carbon monoxide; LVEF = left ventricular ejection fraction; unknown = missing information.